Padman R, Geouque D M, Engelhardt M T
duPont Hospital for Children, Wilmington, Delaware, USA.
Del Med J. 1999 Jan;71(1):13-8.
Previous studies have shown that the Scandipharm Flutter airway clearance device has increased the ability of cystic fibrosis patients to expectorate mucus. Studies that show the effects of the Flutter on pulmonary function among the pediatric cystic fibrosis patients are limited. Thus, we embarked on a study to assess the device's effectiveness.
The long-term effect of the Flutter on pulmonary function tests (PFTs) was studied and compared with other airway clearance techniques, such as chest physiotherapy (CPT) and Vital Signs, Inc. 9000 PEP positive expiratory pressure (PEP) therapy for cystic fibrosis patients of five to 17 years of age with mild to moderate disease. Of the 15 patients who qualified, six completed the study. The patients were evaluated using PFTs and a respiratory assessment at the beginning and end of each new therapy. Duration of each therapy was one month.
No respiratory assessment parameters changed between the therapies studied. All patients who used the Flutter preferred it over the other two therapies. The patients stated they felt better clinically, were able to expectorate mucus more easily, and felt more in control of their therapies. Paired t-test statistical analysis from the PFT data indicated no significant changes in forced expiratory volume in the first second of expiration (FEV1), forced expiratory flow from 25 percent to 75 percent of the loop (FEF25-75), airway resistance (Raw), or specific airway conductance (sGaw) among the three therapies studied.
This study has shown no significant change in respiratory assessment parameters or pulmonary function. Further studies involving multicenter trials are warranted to evaluate the effects of the Flutter on pulmonary function.
先前的研究表明，斯堪迪法姆振颤气道清除装置提高了囊性纤维化患者咳出黏液的能力。显示振颤装置对小儿囊性纤维化患者肺功能影响的研究有限。因此，我们开展了一项研究以评估该装置的有效性。
研究了振颤装置对肺功能测试（PFT）的长期影响，并与其他气道清除技术进行比较，如胸部物理治疗（CPT）以及Vital Signs公司的9000型呼气末正压（PEP）治疗，用于年龄在5至17岁、患有轻至中度疾病的囊性纤维化患者。在符合条件的15名患者中，6名完成了研究。在每种新治疗开始和结束时，使用PFT和呼吸评估对患者进行评估。每种治疗持续时间为1个月。
在所研究的治疗方法之间，呼吸评估参数没有变化。所有使用振颤装置的患者都比其他两种治疗方法更喜欢它。患者表示他们在临床上感觉更好，能够更轻松地咳出黏液，并且对自己的治疗更有掌控感。来自PFT数据的配对t检验统计分析表明，在所研究的三种治疗方法中，第1秒用力呼气量（FEV1）、流量容积环25%至75%之间的用力呼气流量（FEF25 - 75）、气道阻力（Raw）或比气道传导率（sGaw）均无显著变化。
本研究表明呼吸评估参数或肺功能没有显著变化。有必要进行进一步的多中心试验研究以评估振颤装置对肺功能的影响。
